Compare · DSGR vs EW
DSGR vs EW
Side-by-side comparison of Distribution Solutions Group Inc. (DSGR) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- DSGR operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $47.58B, about 29.8x DSGR ($1.59B).
- Over the past year, DSGR is up 16.8% and EW is up 5.3% - DSGR leads by 11.4 points.
- EW has been more active in the news (8 items in the past 4 weeks vs 6 for DSGR).
- EW has more recent analyst coverage (25 ratings vs 1 for DSGR).
- Company
- Distribution Solutions Group Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $1.59B
- $47.58B
- 1M return
- +26.19%
- -7.80%
- 1Y return
- +16.75%
- +5.33%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 8
- Recent ratings
- 1
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest DSGR
- Distribution Solutions Group Announces Timing for Second Quarter Fiscal Year 2026 Results
- Amendment: SEC Form SCHEDULE 13D/A filed by Distribution Solutions Group Inc.
- SEC Form DEFA14A filed by Distribution Solutions Group Inc.
- Distribution Solutions Group Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Regulation FD Disclosure
- TestEquity Expands Environmental Chamber Sales Reach with Millennium Alliance Representation Across the Midwest
- Distribution Solutions Group to Be Taken Private by Affiliates of LKCM Headwater Investments for $35.00 Per Common Share in Cash
- President and CEO Lanuza Cesar was granted 20,000 shares, increasing direct ownership by 25% to 100,498 units (SEC Form 4)
- TestEquity Announces New Executive Leadership Team to Drive Growth as the Leading Distribution Platform for Test and Measurement Solutions, Electronics Production Supplies, and Services
- Director Hillman Lee S was granted 4,601 units of Common Stock - Restricted Stock Units, increasing direct ownership by 4% to 111,862 units (SEC Form 4)
- Director Edelson I Steven was granted 4,601 units of Common Stock - Restricted Stock Units, increasing direct ownership by 5% to 103,284 units (SEC Form 4)
Latest EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves